Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Radiotherapy for liver cancer, and neoadjuvant therapy for rectal cancer

SLAGO 2019

Published: 17 Jul 2019

Views: 1448

Rating:

Save

Dr Parag Parikh - Mayo Clinic, Rochester, USA

Dr Parag Parikh speaks to ecancer at the SLAGO 2019 meeting in Chile about stereotactic radiation for liver cancer, and neoadjuvant therapy for rectal cancer.

Dr Parikh overviews both of his presentations, including treatment options and their placement in the clinical landscape of Latin America.

He finalises by describing the most important steps to take in Latin America to help with treatment.

Related Videos

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer